DIPG Research Highlights from the SNO Conference

Below are some important abstracts in DIPG Research that we would like to highlight. All were presented at the annual Society of Neuro-oncology (SNO) meeting. Click on the links to go to each individual article or a full list of all abstracts can be found here http://neuro-oncology.oxfordjournals.org/content/18/suppl_6.toc. Thank you for reading!

 

PDTB-17. PRE-CLINICAL EVALUATION OF TRAMETINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF DIPG

T Hennika, G Hu, O Becher – Neuro-Oncology, 2016

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer of childhood
with a median survival of less than 1 year from diagnosis. The mitogen-activated protein
kinase (MAPK) pathway (RAS-RAF-MEK1/2-ERK1/2) is a known signaling cascade in…

 

GENT-46. REDUCED p16 EXPRESSION IN A MURINE MODEL OF H3. 3K27M EXPRESSING DIPG SENSITIZES CELLS TO CDK4/6 INHIBITION

F Cordero, G Hu, C Hoeman, O Becher – Neuro-Oncology, 2016

Abstract Diffuse intrinsic pontine glioma (DIPG) remains an incurable pediatric tumor with a
median survival of less than one year and no approved chemotherapy. Recent studies using
DIPG tissue revealed prevalent H3. 3K27M mutations restructure the epigenome. The…


PDTB-05. DEVELOPING A NONINVASIVE IMAGING MARKER FOR ASSESSING THE RESPONSE OF DIFFUSE INTRINSIC PONTINE GLIOMA TO PANOBINOSTAT …

I Park, A Elkhaled, X Yang, Y Zhai, R Sriram… – Neuro-Oncology, 2016

 DIFFUSE INTRINSIC PONTINE GLIOMA GROWTH IN VITRO Y. Linda Wu, Christopher Marnell,
Raymond Chang, Melanie Schweitzer, Uday B. Maachani and Mark Souweidane; Weill Cornell
Medical College, New York, NY, USA Diffuse intrinsic pontine glioma (DIPG) is the 


PDTB-10. INHIBITION OF RADIATION-INDUCED DNA DAMAGE REPAIR MEDIATED CHROMATIN MODIFICATION BY HISTONE H3 DEMETHYLASE INHIBITOR IN …

Q Ma, A Plunti, A Saratsis, R Lulla, JR Fangusaro… – Neuro-Oncology, 2016

 6 Departments of Pathology and Neurosurgery at Northwestern University, Chicago, IL, USA.
Abstract. INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is among the most devastating
childhood cancers, and virtually all patients die within two years after diagnosis. 

 

PDTB-07. CO-CLINICAL STUDY OF PANOBINOSTAT IN AN IMMUNOCOMPETENT GENETICALLY ENGINEERED BRAINSTEM GLIOMA MOUSE MODEL

T Hennika, G Hu, O Becher – Neuro-Oncology, 2016

 Abstract. BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is one of the major
causes of brain tumor-related death in children. Its prognosis has remained poor
despite numerous efforts to improve survival. Panobinostat 


PDTB-12. CNS PENETRATION OF THE CDK4/6 INHIBITOR RIBOCICLIB (LEE011) IN NON-TUMOR BEARING MICE AND MICE BEARING ORTHOTOPIC …

Y Patel – Neuro-Oncology, 2016

 the radiation effect is desperately needed. We have recently shown that inhi- bition of the histone
H3K27 demethylase JMJD3 acts to restore H3K27 methylation in DIPG harboring H3K27M
mutation, while demonstrat- ing potent anti-tumor activity, both in vitro and in vivo. 

 

… DURING AND AFTER RADIATION THERAPY (RT) IN NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND RECURRENT HIGH GRADE …

C Wetmore, D Turner, L Kun, A Onar-Thomas, J Huang… – Neuro-Oncology, 2016

BACKGROUND: Children diagnosed with DIPG have a median survival of less than one
year despite RT, the primary modality of therapy. PDGF pathway activation has been noted
in tumor tissue analyzed from approximately 70% of pediatric DIPG and 50% of HGG…

 

PDTB-20. PRECLINICAL EFFICACY OF ALK2 INHIBITORS IN ACVR1 MUTANT DIPG

D Carvalho, K Taylor, NG Olaciregui, M Valenti… – Neuro-Oncology, 2016

Abstract We recently reported somatic mutations in ACVR1, encoding the serine/threonine
kinase ALK2 receptor, in diffuse intrinsic pontine glioma (DIPG) and have explored its utility
as a novel drug target in these incurable childhood brainstem tumours. 50/206 (24%) DIPG… 

 

PDTB-02. COMBINATORIAL THERAPY WITH PERIFOSINE AND TOPOISOMERASE INHIBITORS SUPPRESSES DIFFUSE INTRINSIC PONTINE GLIOMA GROWTH …

YL Wu, R Chang – Neuro-Oncology, 2016

 DIFFUSE INTRINSIC PONTINE GLIOMA GROWTH IN VITRO Y. Linda Wu, Christopher Marnell,
Raymond Chang, Melanie Schweitzer, Uday B. Maachani and Mark Souweidane; Weill Cornell
Medical College, New York, NY, USA Diffuse intrinsic pontine glioma (DIPG) is the 

 

PDCT-06. DIFFUSE INTRINSIC PONTINE GLIOMA AS A SECONDARY MALIGNANCY: A REPORT FROM THE DIPG REGISTRY AND REVIEW OF THE LITERATURE

M Anderson, B Zon, D Polan, M Matuszak, M Leonard… – Neuro-Oncology, 2016

Abstract Exposure to cranial radiation in childhood increases the risk of subsequent CNS
malignancies, an important cause of late mortality. Studies have shown a linear relationship
between radiation dose and risk of secondary meningiomas and gliomas. However no…

 

PDCT-07. HERBY (BO25041): A PHASE II OPEN-LABEL, RANDOMIZED, MULTICENTER, COMPARATIVE STUDY OF BEVACIZUMAB (BEV)-BASED THERAPY IN …

J Grill, D Hargrave, M Massimino, E Bouffet, A Azizi… – Neuro-Oncology, 2016

 DIFFUSE INTRINSIC PONTINE GLIOMA AS A SECONDARY MALIGNANCY: A REPORT FROM
THE DIPG REGISTRY AND REVIEW OF THE LITERATURE Maia Anderson1, Becky Zon1, Daniel
Polan1, Martha Matuszak1, Marcia Leonard2, Daniel Spratt1, Patricia Robertson2 

 

IMST-09. IDENTIFICATION OF A NOVEL H3. 3. K27M MUTATION-DERIVED NEOANTIGEN EPITOPE AND CLONING OF A SPECIFIC T-CELL RECEPTOR FOR T- …

G Kohanbash, Z Chheda, J Sidney, K Okada… – Neuro-Oncology, 2016

 Devore2, Paul Gonzales2, Sam Broder3, Francois Lebel1 and Laurence Cooper1; 1Ziopharm
Oncology, Boston, MA, USA, 2Translational Drug Development Inc., Scottsdale, AZ, USA, 3Intrexon
Corp., Germantown, MD, USA Diffuse intrinsic pontine gliomas (DIPG) account for 


IMST-07. LOCAL REGULATED IL-12 EXPRESSION AS AN IMMUNOTHERAPY FOR THE TREATMENT OF PONTINE GLIOMA

J Barrett, H Cai, J Miao, K Ludington, C Devore… – Neuro-Oncology, 2016

 Abstract. Diffuse intrinsic pontine gliomas (DIPG) account for 10-25% of pediatric
brain tumors with a grim median survival time of <1 year. Immunotherapy  Controlled
delivery of IL-12 appears to be an effective for DIPG. Based 

 

EXTH-09. LOOKING FOR A CURE: DELTA-24-RDG AND RADIOTHERAPY FOR DIPG TREATMENT

N Martínez-Vélez, MM Sanchez, P Dominguez… – Neuro-Oncology, 2016

Abstract Diffuse Intrinsic Pontine Gliomas (DIPGs) represent the most frequent and the most
aggressive tumor among brainstem gliomas in kids. Radiotherapy is the standard of care
however, in a few months the tumor relapses. Despite advances in genetic knowledge of…

 

Leave a Reply